389 related articles for article (PubMed ID: 16650499)
21. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis.
Maniadakis N; Fragoulakis V; Pallis AG; Simou E; Georgoulias V
Ann Oncol; 2010 Jul; 21(7):1462-1467. PubMed ID: 20019086
[TBL] [Abstract][Full Text] [Related]
23. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Pujol JL; Barlesi F; Daurès JP
Lung Cancer; 2006 Mar; 51(3):335-45. PubMed ID: 16478643
[TBL] [Abstract][Full Text] [Related]
24. Development of docetaxel in advanced non-small-cell lung cancer.
Belani CP; Eckardt J
Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529
[TBL] [Abstract][Full Text] [Related]
25. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
26. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
Copley-Merriman C; Corral J; King K; Whiteside R; Voi M; Dorr FA; McDonald RC
Lung Cancer; 1996 Feb; 14(1):45-61. PubMed ID: 8696720
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Pujol JL; Breton JL; Gervais R; Rebattu P; Depierre A; Morère JF; Milleron B; Debieuvre D; Castéra D; Souquet PJ; Moro-Sibilot D; Lemarié E; Kessler R; Janicot H; Braun D; Spaeth D; Quantin X; Clary C
Ann Oncol; 2005 Apr; 16(4):602-10. PubMed ID: 15741225
[TBL] [Abstract][Full Text] [Related]
28. [Economic evaluation of gemcitabine-cisplatin chemotherapy for non small-cell lung cancer patient in an outpatient setting].
Min SH; Ko SK; Lim JY
Taehan Kanho Hakhoe Chi; 2008 Jun; 38(3):363-71. PubMed ID: 18604145
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Guan H; Liu G; Xie F; Sheng Y; Shi L
Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
[TBL] [Abstract][Full Text] [Related]
30. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Rigas JR
Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
[TBL] [Abstract][Full Text] [Related]
31. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
Bunn PA
Semin Oncol; 1999 Feb; 26(1 Suppl 4):25-30. PubMed ID: 10201518
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
Earle CC; Evans WK
Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group.
Comella P; Frasci G; Panza N; Manzione L; De Cataldis G; Cioffi R; Maiorino L; Micillo E; Lorusso V; Di Rienzo G; Filippelli G; Lamberti A; Natale M; Bilancia D; Nicolella G; Di Nota A; Comella G
J Clin Oncol; 2000 Apr; 18(7):1451-7. PubMed ID: 10735892
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J
Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).
Comella P; Filippelli G; De Cataldis G; Massidda B; Frasci G; Maiorino L; Putzu C; Mancarella S; Palmeri S; Cioffi R; Roselli M; Buzzi F; Milia V; Gambardella A; Natale D; Bianco M; Ghiani M; Masullo P;
Ann Oncol; 2007 Feb; 18(2):324-30. PubMed ID: 17071935
[TBL] [Abstract][Full Text] [Related]
36. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Ohe Y; Ohashi Y; Kubota K; Tamura T; Nakagawa K; Negoro S; Nishiwaki Y; Saijo N; Ariyoshi Y; Fukuoka M
Ann Oncol; 2007 Feb; 18(2):317-23. PubMed ID: 17079694
[TBL] [Abstract][Full Text] [Related]
38. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Cappuzzo F; Rocha Lima CM; Sherman CA; Green MR
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):7-14. PubMed ID: 10960939
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
Thongprasert S; Permsuwan U; Ruengorn C; Charoentum C; Chewaskulyong B
Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]